Investegate |BioNTech SE Announcements | BioNTech SE: BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
Investegate announcements from BioNTech SE, BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
Sylke Maas Fosun Pharma Harveym Friedman University Of Pennsylvania Perelman School Medicine World Health Organization University Of Pennsylvania
Source: investegate.co.uk